NEXT GENERATION

Imaging

Section Editor: Gerald L. Andriole, Jr., MD

Cancer diagnosis and therapy is becoming more focused toward a patient-specific approach to therapy, particularly prostate cancer. The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy. Various imaging modalities and methods may be best suited for different phases of the disease. Our associated physicians discuss the importance of imaging in more detail below.

FEATURED PRESENTATION

Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Phillip J. Koo, MD, chair of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), discusses advances in nuclear medicine and imaging, basic concepts of the theranostic approach, and controversies in this field. Following Dr. Koo’s discussion of the current state of nuclear medicine, Susan F. Slovin, MD, PhD, discusses the three iterations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR).

PLATINUM LECTURES

NEED TO KNOW

ASK THE EXPERT

ADDITIONAL LECTURES

Dr. Koo - Session Review

International Prostate Cancer Update 2021 Session Review: Next Generation Imaging – Focus on PSMA

Phillip J. Koo, MD, summarizes talks from a session he moderated on next generation imaging, with a focus on PSMA, during IPCU 31.
Dr. Helfand - NGI

Next Generation Imaging for Localization of Recurrent Prostate Cancer

Brian T. Helfand, MD, PhD, discusses the efficacy of next generation imaging options for localization of recurrent prostate cancer.
Dr. Barentsz

Recent Advancements in PI-RADS: mpMRI vs. bpMRI

Jelle Barentsz, MD, PhD, discusses recent advancements in PI-RADS and comparative studies of mpMRI and bpMRI.
Dr. Albala - Theranostics

Integrating Theranostics Into a Group Practice

David M. Albala, MD, discusses theranostics and considers its future role as a form of precision medicine for prostate cancer.
Dr. Klotz - TULSA

Treatment for Prostate Cancer with MRI-Guided Transurethral Ultrasound

Laurence Klotz, MD, FRCSC, makes a case for MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer.
Dr. Carroll - PSMA PET

PSMA PET Imaging at Time of Diagnosis

Peter R. Carroll, MD, MPH, summarizes data on PSMA PET and compares its overall efficacy to conventional imaging at the time of diagnosis.
Dr. Finkelstein - Rad Oncol

Radiation Oncology Perspective: Image-Guided Metastasis-Directed Therapy

Steven E. Finkelstein, MD, FACRO, discusses 3 cases of prostate cancer recurrence and their clinical management from a radiation oncology perspective.
Dr. George - VISION

Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

Daniel J. George, MD, reviews the results of the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Dr. Calais - PSMA

Current Status of PSMA Diagnostics

Jeremie Calais, MD, MSc, discusses PSMA diagnostics and compares imaging modalities to establish which modality is ideal for prostate cancer staging.
Dr. Koo - NGI

Next Generation Imaging for Prostate Cancer

Phillip J. Koo, MD, gives an overview of the current state of next generation imaging for prostate cancer and how it compares to conventional imaging.
Dr. Tempany - Risk Assessment Biopsy

Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for Biopsy

Clare Tempany, MD, summarizes evidence for mpMRI’s use in PCa diagnosis, and goes over recent developments in risk assessment & biopsy.
Dr. Iagaru - Molecular Imaging Prostate Cancer

Non-Invasive Molecular Imaging and its Impact on Management of the Localized Disease and Suspected Recurrence

Andrei H. Iagaru, MD, FACNM, enumerates applications of dual radiopharmaceutical-targeted imaging with PSMA & GRPR in prostate cancer care.

SECTION EDITOR

Gerald L. Andriole, Jr., MD
Barnes-Jewish Hospital and Washington University School of Medicine
St. Louis, Missouri

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial as well as PI of the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial, and of the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association, the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons, among other societies.

Supported in part by Blue Earth Diagnostics, Inc.